Pressmeddelande

BioStock: Gabather’s aims to impact the neurodegeneration field

Cision Publicerad: 23 Dec 2022 08:40

Neurodegeneration is a global societal crisis, affecting an increased number of people each year. Despite decades of research, effective therapeutic treatments for diseases like Alzheimer’s and Parkinson’s are still lacking, forcing biotech and pharma companies to pursue an out-of-the-box approach. One of these is Gabather, a Swedish biotech developing drugs based on selective GABA_A receptor modulation – involved in a wide array of neurological disorders, including Alzheimer’s disease. To learn more about the company’s pipeline and plans for 2023, BioStock spoke with CEO Michael-Robin Witt.

Read the interview with Michael-Robin Witt at biostock.se:

https://www.biostock.se/2022/12/gabathers-aims-to-impact-the-neurodegeneration-field/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Gabather

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!